Your session is about to expire
← Back to Search
Procedure
TOETVA for Thyroid Disease
Phase 1
Waitlist Available
Led By Jesse D Pasternak, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
Study Summary
This study is evaluating whether a minimally invasive procedure is safe and feasible for treating trigeminal neuralgia.
Eligible Conditions
- Thyroid Disease
- Surgery
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Length of stay
Neck incision
Post-operative recurrent laryngeal nerve palsy
+8 moreSecondary outcome measures
Quality of Life Score
Trial Design
1Treatment groups
Experimental Treatment
Group I: TOETVAExperimental Treatment1 Intervention
Transoral Endoscopic Thyroidectomy Vestibular Approach
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TOETVA
2019
N/A
~20
Find a Location
Who is running the clinical trial?
University Health Network, TorontoLead Sponsor
1,468 Previous Clinical Trials
484,475 Total Patients Enrolled
Jesse D Pasternak, MDPrincipal InvestigatorUniversity Health Network, Toronto
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger